All In Biotech

Drug Trial Radar · NCT04723810

TumorGlow Intraoperative Molecular Imaging (IMI)

A Study to Evaluate the Safety and Efficacy of Indocyanine Green for Intraoperative Molecular Imaging of Solid Tumors (TumorGlow™)

Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Aug 14, 2024

Primary completion

Jan 14, 2027

Study completion Jan 14, 2027

Sponsor

Lead sponsor
University of PennsylvaniaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 study in patients presenting with any solid tumor and/or diseased tissue even benign nodules presumed to be resectable and at risk for recurrence on pre-operative assessment who are considered to be good surgical candidates to evaluate the safety and efficacy of the image-guided surgery using indocyanine green for intramolecular imaging of solid tumors.

Conditions

  • Tumor, Solid

Interventions

  • Indocyanine GreenDrug

    The investigational drug is indocyanine green, single dose between 1-5 mg/kg diluted into sterile water for intravenous (IV) injection up to 5 days prior to resection surgery. The actual dose and timing from dose to imaging will be determined based on tumor type.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Determine the safety of indocyanine green (all tumor types combined)Time frame: Up to 5 days
  2. Cohort 1: Identify optimal dosing of indocyanine green before surgery, and camera combination (tumor type-specific)Time frame: Up to 5 days
  3. Cohort 1: Identify optimal timing of indocyanine green before surgery, and camera combination (tumor type-specific)Time frame: Up to 5 days
  4. Cohort 2: Determine the sensitivity and specificity of indocyanine green (tumor type-specific)Time frame: Up to 5 days
  5. Cohort 2: Confirm the efficacy of indocyanine green used with Near Infrared (NIR) fluorescent imaging as measured by Clinically Significant Event (CSE) rate (tumor type-specific)Time frame: Up to 5 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.